ASPG and acute lymphoblastic leukemia: However, few investigations have focused on asparaginase use in AYA patients.90–92 Douer et al. evaluated asparaginase pharmacokinetics in adult patients (aged 17–55 years) with ALL.90 Twenty-five newly diagnosed patients were administered a single dose of PEG-asparaginase 2000 IU/m2 during induction.